73 related articles for article (PubMed ID: 17329185)
1. Quantitative measures of oestrogen receptor and ERBB2 expression.
Hayes DF
Lancet Oncol; 2007 Mar; 8(3):184-5. PubMed ID: 17329185
[No Abstract] [Full Text] [Related]
2. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer.
Dressman MA; Baras A; Malinowski R; Alvis LB; Kwon I; Walz TM; Polymeropoulos MH
Cancer Res; 2003 May; 63(9):2194-9. PubMed ID: 12727839
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
[TBL] [Abstract][Full Text] [Related]
6. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
7. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
Gong Y; Yan K; Lin F; Anderson K; Sotiriou C; Andre F; Holmes FA; Valero V; Booser D; Pippen JE; Vukelja S; Gomez H; Mejia J; Barajas LJ; Hess KR; Sneige N; Hortobagyi GN; Pusztai L; Symmans WF
Lancet Oncol; 2007 Mar; 8(3):203-11. PubMed ID: 17329190
[TBL] [Abstract][Full Text] [Related]
8. [Hormone-dependence and C-ERBB2: relationship between estrogen receptor expression, estrogen-regulated proteins, and C-ERBB2 in breast carcinoma].
Costarelli L; Piro FR; Fortunato L; Vitelli CE; Farina M; Taffuri M; Amini M
Suppl Tumori; 2005; 4(3):S171. PubMed ID: 16437968
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of the UROC28 gene in human breast cancer: relationship to ERBB2 gene expression.
Kamagata C; Tsuji N; Kondoh K; Sasaki M; Kobayashi D; Yagihashi A; Watanabe N
Anticancer Res; 2002; 22(6C):4087-91. PubMed ID: 12553037
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
Ariazi EA; Clark GM; Mertz JE
Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
[TBL] [Abstract][Full Text] [Related]
11. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen.
Perissi V; Menini N; Cottone E; Capello D; Sacco M; Montaldo F; De Bortoli M
Oncogene; 2000 Jan; 19(2):280-8. PubMed ID: 10645007
[TBL] [Abstract][Full Text] [Related]
12. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
13. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
14. Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer.
Kaklamani VG; Cianfrocca M; Ciccone J; Kindy K; Rademaker A; Wiley EL; Gradishar W; O'Regan RM
Biomarkers; 2010 Mar; 15(2):191-3. PubMed ID: 19839717
[No Abstract] [Full Text] [Related]
15. HER2 and proliferation of wound-induced breast carcinoma.
Tez M; Göçmen E; Ozçelik T
Lancet; 2003 Nov; 362(9394):1503; author reply 1503. PubMed ID: 14602459
[No Abstract] [Full Text] [Related]
16. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
[TBL] [Abstract][Full Text] [Related]
17. Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
19. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.
Guarneri V; Giovannelli S; Ficarra G; Bettelli S; Maiorana A; Piacentini F; Barbieri E; Dieci MV; D'Amico R; Jovic G; Conte P
Oncologist; 2008 Aug; 13(8):838-44. PubMed ID: 18650259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
